Pregled bibliografske jedinice broj: 1031197
Prevention of Infectious Complications in Acute Pancreatitis: Results of a Single-Center, Randomized, Controlled Trial.
Prevention of Infectious Complications in Acute Pancreatitis: Results of a Single-Center, Randomized, Controlled Trial. // Pancreas, 48 (2019), 1056-1060 doi:10.1097/MPA.0000000000001368. (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1031197 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Prevention of Infectious Complications in Acute
Pancreatitis: Results of a Single-Center,
Randomized, Controlled Trial.
Autori
Goran, Poropat ; Anja, Radovan ; Perić, Matija ; Ivana, Mikolasević ; Vanja, Giljača ; Goran, Hauser ; Sandra, Milić ; Davor, Štimac
Izvornik
Pancreas (0885-3177) 48
(2019);
1056-1060
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
PAncreatitis, infection
Sažetak
Abstract OBJECTIVES: This study aimed to investigate the efficiency of imipenem to prevent infectious complications in predicted severe acute pancreatitis (AP). METHODS: Consecutive AP patients were randomized to imipenem 3 × 500 mg intravenously daily or an identical placebo. Exclusion criteria were prior AP, chronic pancreatitis, active malignancy, immune deficiency, active infection, concomitant antibiotic treatment, pregnancy, and patients younger than 18 years. Infectious complications including infected pancreatic necrosis, pneumonia, urinary tract infection, positive blood cultures, sepsis, and other infections were assessed as the primary outcome. Secondary outcomes included mortality, persistent organ failure, systemic inflammatory response syndrome, local complications, serious adverse events, and need for surgical intervention. RESULTS: Forty-nine patients were randomized to each group. Infectious complications were present in 10 versus 12 of 49 patients (relative risk [RR], 0.833 ; 95% confidence interval [CI], 0.398-1.747). There were no significant differences in infected pancreatic necrosis (RR, 1.5 ; 95% CI, 0.262-8.588), pneumonia (RR, 1.5 ; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6 ; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5 ; 95% CI, 0.047-5.336), sepsis (RR, 0.333 ; 95% CI, 0.036- 3.095), and other (RR, 1.333 ; 95% CI, 0.315- 5.648). We found no significant differences in secondary outcomes. CONCLUSIONS: Concordantly to available evidence, there is currently no ground to support prophylactic use of antibiotics in predicted severe AP.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Fakultet zdravstvenih studija u Rijeci
Profili:
Sandra Milić
(autor)
Goran Hauser
(autor)
Vanja Giljača
(autor)
Goran Poropat
(autor)
Ivana Mikolašević
(autor)
Davor Štimac
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE